{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-013774","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2022-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.866024+00:00","generated_at":"2026-06-27T16:48:25.859237+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Annexon appoints Dr. Bettina Cockroft to board of directors","bullets":["Dr. Cockroft is SVP and CMO of Sangamo Therapeutics, effective immediately.","Appointed as Class III director with term expiring at 2023 annual meeting.","Receives $35,000 annual retainer, initial option for 20,000 shares, and annual grant for 10,000 shares.","She brings nearly 20 years of clinical development experience in neurodegenerative and movement disorders.","Annexon highlights her expertise as it advances complement-mediated therapies in GBS and Huntington's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-013774","json":"https://secwatch.observer/filing/0001193125-22-013774.json","markdown":"https://secwatch.observer/filing/0001193125-22-013774.md","text":"https://secwatch.observer/filing/0001193125-22-013774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312522013774/0001193125-22-013774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312522013774/d477760d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T16:48:25.859237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e335e4fdbb","claim":"Bettina M. Cockroft was appointed as Director at Annexon, Inc..","evidence_excerpt":"On January 19, 2022, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., to the Board, effectively immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312522013774/0001193125-22-013774-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}